Monitor for any conversion of this 13G to a 13D, which would signal activist intent. For now, this is a routine post-merger disclosure by a passive institutional investor.
Price Chart
Executive Summary
Wellington Biomedical Innovation Master Investors (Cayman) II L.P. filed a Schedule 13G disclosing a 6.1% passive stake in Korsana Biosciences (formerly Cyclerion Therapeutics), representing 2,775,788 shares. This filing comes just days after the company completed its reverse merger with Korsana on September 8, 2026, and is likely a post-merger disclosure of a PIPE investor's holdings. The passive nature and the context of the recent merger make this a routine filing with limited standalone impact.
Key Financial Metrics
Key Facts
- Wellington Biomedical Innovation Master Investors (Cayman) II L.P. disclosed beneficial ownership of 2,775,788 shares of Korsana Biosciences common stock.
- The stake represents 6.1% of the outstanding shares.
- The filing is a Schedule 13G, indicating passive investment intent with no control or influence objectives.
- The filing date is September 16, 2026, just 8 days after the reverse merger closed on September 8, 2026.
- The filer is a Cayman Islands exempted limited partnership, likely a PIPE investor from the merger financing.
Financial Impact
6.1% passive stake valued at approximately $2.8M based on 2,775,788 shares (no per-share price provided in filing).
Risk Factors
- The filer could later convert to a 13D and become activist, though no indication of that now.
- The 6.1% stake could be sold in the open market without prior notice, potentially pressuring the stock.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0001903360-26-000015 |
| Document: 0001903360-26-000015-index.html | 0001903360-26-000015 |
| Document: 0001903360-26-000015.txt | 0001903360-26-000015 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 144 | $31.31 | awaiting T+20 | — | $30.75 (−1.79%) |
Oct 15, 2026 11d ago | SC 13G/A | $32.38 | awaiting T+20 | — | $30.75 (−5.03%) |
Oct 15, 2026 11d ago | DEF 14A | $32.38 | awaiting T+20 | — | $30.75 (−5.03%) |
Sep 23, 2026 4w ago | 144 | $37.19 $33.43 | ▼ −10.11% | ▼ −9.69% | $30.75 (−17.32%) |
Sep 22, 2026 4w ago | 144 | $32.30 $32.54 | ▲ +0.74% | ▲ +0.06% | $30.75 (−4.80%) |
Sep 18, 2026 5w ago | SC 13G | $33.21 $31.41 | ▼ −5.42% | ▼ −4.51% | $30.75 (−7.41%) |
Sep 18, 2026 5w ago | 144 | $33.21 $31.41 | ▼ −5.42% | ▼ −4.51% | $30.75 (−7.41%) |
Sep 16, 2026 5w ago | SC 13G | $31.23 $34.32 | ▲ +9.89% | ▲ +7.83% | $30.75 (−1.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers